These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 30779635)

  • 41. Association between cytochrome P450 2C19 polymorphism and clinical outcomes in clopidogrel-treated Uygur population with acute coronary syndrome: a retrospective study.
    Yu L; Wang T; Bai H; Zhu W; Li Y; Wu J; Liu W; Sun L; Yu A; Li H
    BMC Cardiovasc Disord; 2021 Aug; 21(1):391. PubMed ID: 34384383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical impact of preemptive pharmacogenomic testing on antiplatelet therapy in a real-world setting.
    Massmann A; Christensen KD; Van Heukelom J; Schultz A; Shaukat MHS; Hajek C; Weaver M; Green RC; Wu AC; Hickingbotham MR; Zoltick ES; Stys A; Stys TP
    Eur J Hum Genet; 2024 Aug; 32(8):895-902. PubMed ID: 38424298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients.
    Claassens DMF; Gimbel ME; Bergmeijer TO; Vos GJA; Hermanides RS; van der Harst P; Barbato E; Morisco C; Tjon Joe Gin RM; de Vrey EA; Heestermans TACM; Jukema JW; von Birgelen C; Waalewijn RA; Hofma SH; den Hartog FR; Voskuil M; Van't Hof AWJ; Asselbergs FW; Mosterd A; Herrman JR; Dewilde W; Mahmoodi BK; Deneer VHM; Ten Berg JM
    Int J Cardiol; 2021 Jul; 334():10-17. PubMed ID: 33887342
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
    Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
    Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.
    Lyu SQ; Yang YM; Zhu J; Wang J; Wu S; Zhang H; Shao XH; Ren JM
    Platelets; 2020 Nov; 31(8):971-980. PubMed ID: 32546030
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
    Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
    Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of the effect of CYP2C19 polymorphism on clinical outcome between acute coronary syndrome and stable angina.
    Arima Y; Hokimoto S; Akasaka T; Mizobe K; Kaikita K; Oniki K; Nakagawa K; Ogawa H
    J Cardiol; 2015 Jun; 65(6):494-500. PubMed ID: 25156215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Is a genotype-guided therapy the optimal strategy to personalize anti-thrombotic management in patients with acute coronary syndrome?
    van den Broek WWA; Ten Berg JM
    Eur Heart J; 2022 Nov; 43(43):4599-4600. PubMed ID: 35678582
    [No Abstract]   [Full Text] [Related]  

  • 49. The Frequency of the Minor Polymorphisms in the
    Zelenskaya EM; Lifshits GI; Nikolaev KY; Donirova OS; Altayev VD; Apartsin KA; Voronina EN; Protasov KV; Sychev DA
    Genet Test Mol Biomarkers; 2020 Jun; 24(6):338-342. PubMed ID: 32392440
    [No Abstract]   [Full Text] [Related]  

  • 50. Advances in the Pharmacogenomics of Antiplatelet Therapy.
    Akhtar T; Bandyopadhyay D; Ghosh RK; Aronow WS; Lavie CJ; Yadav N
    Am J Ther; 2020; 27(5):e477-e484. PubMed ID: 31498157
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Genotype-Guided Selection of Antiplatelet Therapy: The Evidence Moves East.
    Cavallari LH; Franchi F
    JACC Cardiovasc Interv; 2023 Apr; 16(7):844-846. PubMed ID: 36898938
    [No Abstract]   [Full Text] [Related]  

  • 52. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
    Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL
    Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.
    Giusti B; Gori AM; Marcucci R; Saracini C; Sestini I; Paniccia R; Valente S; Antoniucci D; Abbate R; Gensini GF
    Pharmacogenet Genomics; 2007 Dec; 17(12):1057-64. PubMed ID: 18004210
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
    Jiang M; You JH
    Expert Opin Pharmacother; 2015 Apr; 16(5):771-9. PubMed ID: 25660101
    [TBL] [Abstract][Full Text] [Related]  

  • 55.
    Ellithi M; Baye J; Wilke RA
    Pharmacogenomics; 2020 Aug; 21(12):889-897. PubMed ID: 32723143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized Comparisons of Double-Dose Clopidogrel or Adjunctive Cilostazol Versus Standard Dual Antiplatelet in Patients With High Posttreatment Platelet Reactivity: Results of the CREATIVE Trial.
    Tang YD; Wang W; Yang M; Zhang K; Chen J; Qiao S; Yan H; Wu Y; Huang X; Xu B; Gao R; Yang Y;
    Circulation; 2018 May; 137(21):2231-2245. PubMed ID: 29420189
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention.
    Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC
    Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention.
    Cavallari LH
    Expert Rev Cardiovasc Ther; 2017 Aug; 15(8):581-589. PubMed ID: 28699807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Implementation of Cell Samples as Controls in National Proficiency Testing for Clopidogrel Therapy-Related CYP2C19 Genotyping in China: A Novel Approach.
    Lin G; Yi L; Zhang K; Wang L; Zhang R; Xie J; Li J
    PLoS One; 2015; 10(7):e0134174. PubMed ID: 26218263
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Projected impact of pharmacogenomic testing on medications beyond antiplatelet therapy in percutaneous coronary intervention patients.
    Black RM; Williams AK; Ratner L; Crona DJ; Wiltshire T; Weck KE; Stouffer GA; Lee CR
    Pharmacogenomics; 2020 May; 21(7):431-441. PubMed ID: 32343201
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.